Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) are both uncommon disorders that present with a microangiopathic hemolytic anemia and thrombocytopenia. Although for TTP, neurologic manifestations predominate, and in HUS renal dysfunction is virtually always present, there is significant overlap in their clinical presentation. In recent years, tremendous progress has been made in our understanding of the pathogenesis of these disorders. It is now apparent that there are subcategories of both TTP and HUS that can differ in their clinical manifestations, etiology, and management. For instance, although most cases of HUS are due to infection with organisms that produce Shiga-like toxin, other cases may be caused by defined genetic abnormalities. Similarly, TTP is usually caused by genetic or acquired deficiency of the ADAMTS13 enzyme; however, in other cases the relationship with this enzyme remains to be established. Management includes supportive care, plasma transfusions for genetic protein deficiencies, and plasma exchange transfusion for autoimmune TTP.
Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) are both causes of microangiopathic hemolytic anemias in children and adolescents. In the last few years, significant progress has been made in the understanding of the pathogenesis of these two disorders. This review discusses the pediatric features of TTP and HUS. Given that much of the information about recent advances in the understanding of the pathophysiology of TTP and HUS is discussed elsewhere in this issue, we limit our discussion of these aspects to those that influence children and adolescent illness.
TTP and HUS are discussed separately. In general, there are significant differences in their etiologies, clinical features, epidemiology, treatment, and outcome. In addition, it is now recognized that both congenital and acquired forms of TTP and HUS exist. In the following sections, we endeavor to describe the molecular etiology, the clinical manifestations, laboratory diagnosis, and treatment approaches for each of these disorders. The reader should keep in mind, however, that there can be overlap between each aspect of these two illnesses. At present, no one factor completely separates the diagnosis of TTP from HUS.
MICROANGIOPATHIC HEMOLYTIC ANEMIA Thrombotic microangiopathy is defined by endothelial cell damage, resulting in platelet thrombosis, leading to vessel obstruction. Histologically, this is manifested by accumulation of platelet thrombi containing von Willebrand factor (vWF) with very little fibrin in TTP 1 or platelet-fibrin thrombi in HUS and disseminated intravascular coagulation (DIC) 2 in the vasculature of specific organs, especially the brain in TTP and the kidneys in HUS. Red cell destruction occurs in the vessels narrowed by these thrombi, leading to schistocyte formation. Hence, the peripheral blood smear in these disorders characteristically reveals schistocytes, helmet cells, polychromasia, and thrombocytopenia. In addition to TTP and HUS, other disorders that can present with a microangiopathic anemia in this age group are shown in Table 1 . Unlike DIC, blood samples from patients with HUS and TTP typically show normal values for fibrinogen, prothrombin times (PTs), and activated partial thromboplastin times (aPTTs). HUS is usually considered to be a pediatric disease, although it may occur in adults, whereas TTP is much more common in adults and relatively rare in persons < 21 years of age.
HEMOLYTIC-UREMIC SYNDROME

Etiology and Pathophysiology
The term HUS was first used in 1955 when Conrad von Gasser et al 3 reported a case series of five children with thrombocytopenia, hemolytic anemia, and renal failure. 3 Fifty years later, HUS is still defined by that clinical triad. Fortunately, during the last 50 years, we have seen significant progress toward elucidating the etiology and pathophysiology of HUS. Although several distinct etiologies of HUS exist, approximately 90% of HUS in children is caused by Shiga toxin-producing Escherichia coli.
4,5
Shiga Toxin-Induced HUS (typical HUS) Several strains of E. coli produce a toxin similar to Shigella dysenteriae serotype 1. This toxin was found to be cytotoxic to Vero cells (African green monkey kidney cells), 6 and E. coli that produce this toxin have been termed subsequently verotoxin or Shiga-like toxin-producing E. coli (STEC). 7 Although many E. coli serotypes produce Shiga-like toxin, [8] [9] [10] [11] [12] [13] [14] [15] the most common STEC is E. coli, expressing the somatic (O) antigen 157 and the flagellar (H) antigen 7. E. coli O157:H7 colonizes cattle, deer, sheep, goats, and horses, and is transmitted through a variety of food sources, water sources, and person-toperson contact. The bacterium is extremely hardy; it has been identified in sawdust 42 weeks after an associated outbreak. 16 Following the ingestion of contaminated food or water, the bacteria bind to the gastrointestinal mucosa causing diarrhea. The E. coli then produce a toxin that enters the circulation through the inflamed intestinal epithelial cells. Because neither toxin nor bacteria is identified in the circulation, it is speculated that the toxin is transported to the site of injury bound to polymorphonuclear leukocytes. 17 However, other cell types including platelets 18 and monocytes 2 can bind Shiga toxin. The toxin consists of pentamers of binding subunits (B) that surround a single enzymatic subunit (A). At the site of injury, the B subunits bind to the membrane receptor globotriaosylceramide (Gb3) on the cell surface. 19 The toxin is then internalized, where it inhibits protein synthesis, leading to cell damage and death. Differences in expression of Gb3 might explain the preferential damage to the kidney because glomerular endothelial cells express a very high level of Gb3.
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The hematologic consequences of infection with STEC are a direct result of toxic injury to the endothelium. The vascular endothelium is a dynamic surface. Normally, the endothelial surface inhibits platelet adherence and thrombin generation. However, when damaged, these properties change and the endothelial surface can promote thrombin generation, resulting in fibrin deposition and formation of platelet-fibrin thrombi. In addition, fibrinolysis is inhibited by increased activity of plasminogen activator inhibitor 1, further increasing the prothrombotic milieu. 22, 23 In addition, separation of endothelial cells from their attachment to the basement membrane exposes the blood to the adhesive and prothrombotic elements of the basement membrane including collagen and vWF. 24 The result of this endothelial injury is platelet activation, thrombosis, and thrombotic injury; it is this thrombotic injury of the microvasculature of the kidney that causes the clinical triad of HUS (microangiopathic hemolytic anemia, thrombocytopenia, and renal dysfunction). 25 In addition to causing endothelial cell damage, the Shiga toxin possesses other traits that contribute to the development of HUS. The toxin has been shown to induce expression of tumor necrosis factor (TNF)-a, which upregulates the Gb3 receptor, causing more toxin to be delivered to the cell. 26 Shiga toxin, when associated with TNF-a, causes an increased expression of tissue factor, 27 which then activates factor VII, ultimately leading to thrombin formation, subsequent platelet activation, and fibrin generation. Shiga toxin can also directly injure monocytes, 28 which are another source of tissue factor and inflammatory cytokines. Lastly, several types of renal cells have receptors for Shiga toxin, 20, 29 suggesting that renal injury might be a combination of thrombotic injury and direct injury by the toxin to the parenchymal cells.
Atypical HUS
Although STEC induced HUS is a relatively homogeneous disease, atypical HUS is very heterogeneous. Atypical HUS arises from numerous causes, including cancer, 30 drugs, 31 bone marrow transplantation, 5 autoimmune disorders, and disorders of intracellular cobalamin metabolism. 32 The two most common etiologies of atypical HUS are Streptococcus pneumoniae infection and abnormalities of complement regulation.
HUS is a complication of S. pneumoniae infection in an estimated 0.6% of invasive S. pneumoniae cases.
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S. pneumoniae possess a neuroaminidase, which cleaves the N-acetyl neuraminic acid, resulting in the exposure of a cryptic T antigen present on erythrocytes and endothelial cells.
34 Naturally occurring anti-T immunoglobulin (IgM) then reacts with this antigen, injuring red blood cells and endothelial cells to cause HUS. Interestingly, HUS secondary to S. pneumoniae is almost exclusively associated with invasive disease, 35,36 lending credit to the theory that a large bacterial load and/or severe inflammation are required as cofactors for the development of HUS.
Disorders of complement regulation have also been described as a cause of atypical HUS. 2, 37 Complement is an important part of a person's innate immunity. Fully activated complement is capable of killing cells and organisms. The activation products are closely regulated by proteins such as factor H, factor I, and membrane cofactor protein (MCP). Factor H binds to C3b, and as a cofactor for factor I, accelerates the decay of the alternate complement pathway convertase, destroying C3 convertase activity. Complement factor I cleaves the a chains of C3b and C4b, inactivating these enzymes, thus preventing the formation of C3/C5 convertases. MCP is a cofactor for factor I in the cleavage of C3b and C4b. Disorders of complement regulation result in uninhibited activated complement, with subsequent endothelial damage and thrombotic microangiopathy. Mutations in factor H, 38-42 factor I, 43 and MCP 44, 45 have been reported to cause HUS. Most defects are congenital but an acquired factor H deficiency secondary to autoantibodies has been reported. 46 Because most of the abnormalities in complement regulation are recent discoveries, it is likely that additional disorders of the complement system will be implicated as causes of HUS.
The role of ADAMTS13 (named for the combination of a disintegrin-like and metalloprotease with thrombospondin type 1 motifs) in HUS is much less clear. Most studies have shown that the ADAMTS13 levels are normal or nearly normal in patients with HUS. 47, 48 However, some cases of atypical HUS secondary to the classic defect in TTP (ADAMTS13 deficiency) have been reported. 49, 50 This overlap in pathogenesis is of utmost importance when considering the work-up for a patient with microangiopathic anemia and thrombocytopenia.
Clinical Manifestations of HUS
HUS is the most common cause of acute renal failure in children. 51 The syndrome is defined by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and renal impairment. However, the pathogenesis leading to HUS can alter the clinical manifestations vastly. Table 2 lists a comparison of TTP, STEC-related HUS, and atypical HUS.
Typical childhood HUS is a complication of a STEC infection (most commonly E. coli O157:H7). Approximately 3 days (range, 1 to 12 days) following ingestion of the bacteria, nonbloody diarrhea occurs. After 2 days of nonbloody diarrhea and vomiting, the diarrhea becomes painful and bloody. Although most children infected with STEC develop bloody diarrhea, 11 ,52 a large subset only develop nonbloody diarrhea. In fact, some patients have no gastrointestinal symptoms but do have evidence of STEC infection. 11, 53 In addition, HUS following a urinary tract infection with STEC has been reported. 54 Therefore, diarrhea should not be used to differentiate typical versus atypical HUS.
The incidence of HUS varies in different parts of the world, with estimates between 0.3 and 3.3 cases per 100,000 children. [11] [12] [13] [14] In a review of either insurance files (United States) or computerized medical records (United Kingdom and Saskatchewan, Canada) from the years 1990 to 2000, Miller et al 55 calculated the incidence rates for HUS to be 2.7 per million patient-years in the United States and 2.1 per million patient-years in the United Kingdom and Saskatchewan. Of note, the incidence rates were higher from 1995 to 2000 than in the preceding 5 years. STEC-associated HUS usually occurs in young children, with 75% of cases occurring before age 5.
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HUS occurs 7 to 14 days after initial symptoms in approximately 5 to 15% of children who present with STEC infection.
22,56-58 Many children with STEC infection develop the hematological abnormalities of HUS but have normal renal function (incomplete HUS). 59 An explanation of incomplete HUS is revealed in the seminal article, which demonstrated that thrombotic changes can be found during the acute diarrheal phase of many patients who do not proceed onto HUS. 22 It is unclear why some children with STEC infections develop HUS and others do not; it may be a net effect of E. coli virulence, toxin load, and host factors.
HUS has significant associated morbidity and mortality. Anemia and thrombocytopenia occur in all patients, with red blood cell transfusion support required in many cases. Renal complications are common, with dialysis required in 50 to 60% of children. 11, 52 Dialysis is usually temporary, lasting 5 to 7 days when required. 5 Acute and chronic hypertension are also complications of impaired renal function. Renal injury progressing to endstage renal failure and kidney transplantation is rare in STEC-associated HUS. Gastrointestinal complications including cholelithiasis and pancreatitis are also common. [60] [61] [62] Although neurological complications (seizures, altered mental status, etc.) are thought of as complications of TTP, they occur in approximately 25% of children with HUS . 11, 62, 63 Death occurs in approximately 2 to 4% of HUS cases. 4, 8, 11, 13, 64 Although detailed studies are scarce, there appears to be no clinical difference in outcome between HUS secondary to E. coli O157 and non-O157 STEC cases.
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Atypical HUS accounts for approximately 10% of HUS cases in children. Although definitive incidence data are lacking, abnormalities of complement regulatory proteins can present in the newborn period, whereas HUS secondary to S. Pneumoniae infection can present at all ages. S. pneumoniae is the most common etiology of atypical HUS, accounting for 38% of cases in one series. 62 The hematological, neurological, renal, and gastrointestinal manifestations of atypical HUS are similar in nature to those of typical HUS. These complications have been thought to be more frequent and severe in atypical HUS. 62 Brandt et al 60 reviewed 58 cases of HUS secondary to S. pneumoniae and found a mortality rate of 24%. However, at least one group has reported fewer acute renal complications and no increase in mortality. 65 Undisputed, however, is the fact that relapse rates for patients with abnormalities of complement regulatory proteins are much higher than for other causes of HUS. 42 Noris et al 66 found that 62% of patients with familial HUS died and that there was a high frequency of renal failure in the survivors. Of those undergoing renal transplantation, 16% will lose their graft in the first month. 2 
Diagnostic Studies
The clinical scenario and laboratory values alone are often sufficient to suggest strongly the diagnosis of HUS. Confronted with a child who has microangiopathic hemolytic anemia and thrombocytopenia, one should begin to examine possible etiologies listed in Table 1 . In patients with diarrhea, one should instigate an investigation for a Shiga toxin-producing organism or the toxin itself. Stool culture on sorbitol-MacConkey agar will detect most E. coli O157 infections but will miss non-O157 STEC because they usually ferment sorbitol. 67 Therefore, direct detection of the Shiga toxin in the stool is required to identify all serotypes of STEC. In patients without diarrhea, the investigation needs to be broader. First, the clinician needs to evaluate other etiologies such as drugs, DIC, TTP, and other illnesses that may mimic the disease (Table 1) . Second, given that many cases of nondiarrheal HUS were proven to be caused by STEC, a search for STEC is warranted through examination of stool and urine.
25 C3 levels should be sent to screen for possible complement factor deficiencies. Factors H, I, and MCP should also be measured. It should be noted that in some cases of factor H deficiency, the defect is qualitative, not quantitative, leading to a misleading result of normal factor H levels. 38, 68 Lastly, urinary methylmalonic acid levels can be obtained to evaluate for the rare disorder of intracellular cobalamin metabolism, especially in children with clinical features such as developmental delay and macrocytic anemia. 69 Treatment of HUS The mainstay of treatment for HUS is supportive care. Early recognition and early intravenous volume expansion have been shown to provide renal protection. 70 The challenge is to provide sufficient intravenous fluids to maintain renal perfusion while avoiding fluid overload. As such, we recommend the hospitalization of children with HUS to provide continuous monitoring and correction of volume depletion or overload.
Children with HUS can become severely anemic. Packed red cell transfusions should be used if clinically indicated. Conversely, despite thrombocytopenia, platelets should be given only when absolutely necessary, such as for life-threatening hemorrhage, because they could potentially exacerbate the platelet-fibrin thrombosis.
TYPICAL HUS
Antibiotics should not be administered routinely to children with STEC, given that most studies have shown no benefit 57 or higher rates of HUS. 58 However, if there is consideration of S. pneumoniae-induced HUS, early antibiotic therapy to cover that organism is indicated, as discussed in the section ''Atypical HUS''. Many other treatments including corticosteroids, plasmapheresis, and heparin have been used without any clear benefit. 25 Our better understanding of STEC-associated HUS has resulted in new treatment proposals to try either monoclonal antibodies against Shiga toxin 71 or Shiga toxin receptor analogs 72 to prevent the disease. However, the utility of these treatments has yet to be proven.
Prevention might be the most important treatment available for HUS. Awareness of the disease increased significantly with the described outbreak in the 1990s. 73 This increased public awareness provided a platform for improved standards for meat processing, food handling, and food preparation. Although many of the initial outbreaks described were associated with fastfood hamburger meat, there have been no reported similar outbreaks since 1995, indicating that the increased awareness and preventive measures may have helped. 56 Hand washing should be performed to prevent person-to-person contamination.
ATYPICAL HUS
Treatment for HUS secondary to S. pneumoniae involves mainly supportive care as described above. Theoretically, because the anti-T IgM antibodies are the primary cause of the HUS, one can avoid administering additional anti-T immunoglobulins by washing red blood cells or platelets prior to any transfusion (although this has not been shown to be effective). Early appropriate antibiotic therapy should be initiated if invasive S. pneumoniae infection is considered likely. If patients do develop end-stage renal disease, renal transplantation should be considered because HUS is unlikely to recur as long as there is no inherited complement deficiency.
Treatment for defects within the complement regulatory system varies. Treatment with plasma infusions has resulted in recovery of kidney function by stopping the complement activation. 74, 75 Theoretically, chronic plasma replacement should be an effective treatment for these disorders. Unfortunately, many patients progress to end-stage renal disease. Treatment then has been kidney transplantation. A large majority of patients have experienced relapse following transplantation 9,43,76-78 because the inherited defect has not been repaired. As such, there has been at least one attempt to treat factor H deficiency with a liver transplantation. 79 Lastly, although renal transplantation may not correct factor H deficiency, because MCP is a transmembrane protein, a kidney transplantation should rectify the problem.
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THROMBOTIC THROMBOCYTOPENIC PURPURA TTP is generally a disorder of adults; < 10% of cases occur in the pediatric age group. 55 The original case of TTP reported by Moschcowitz 80 occurred in a 16-yearold girl. It is now recognized that TTP can occur as a congenital disorder due to a mutation in the gene coding for the vWF-cleaving protease (ADAMTS13), can be caused by acquired inhibitors to that enzyme, or can be due to other causes of endothelial cell damage.
ADAMTS13 is one of a family of currently known 19 metalloprotease enzymes (ADAMTS) with multiple described functions. Disorders associated with defects in other ADAMTS enzymes include type VII C Ehlers-Danlos syndrome (ADAMTS2) 81 and WeillMarchesani syndrome (ADAMTS10). 82 The gene for ADAMTS13 has been localized to chromosome 9q34 83 and codes for a 1427-amino acid protein.
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ADAMTS13 cleaves vWF released from the endothelial cell, decreasing its multimeric size. Unlike the vWF multimer usually found in plasma, the ultralarge von Willebrand factor multimer (ULvWF) stored in Weibel-Palade bodies in endothelial cells, if released into plasma, can induce platelet thrombus formation immediately when exposed to high shear stress. There is increasing evidence that the presence of ULvWF in the plasma due to defective or absent ADAMTS13 is a key component in the pathogenesis of most cases of TTP.
CHRONIC RELAPSING TTP/CONGENITAL TTP (UPSHAW-SCHULMAN SYNDROME) In 1960, Schulman et al 84 described an 8-year-old girl with recurrent bleeding, thrombocytopenia, and hemolysis who had a clinical response to plasma infusions. In 1978, Upshaw 85 described a very similar case and theorized that an absent plasma factor was the underlying cause. Since then, there have been several reports of similar infants and children. 86 The typical presentation of chronic relapsing TTP is that of a normal newborn who within the first several hours or days of life develops severe hyperbilirubinemia, hemolytic anemia, and thrombocytopenia. 87 Unlike in DIC, the fibrinogen level is typically not decreased. 88, 89 Hyperbilirubinemia may be severe, exchange transfusion is often required, and kernicterus has been reported with chronic relapsing TTP. 90, 91 These infants usually respond rapidly to exchange transfusion or even simple platelet transfusion. 89 Because of the response to transfusion or exchange transfusion, the infants are often discharged home with a presumptive diagnosis of DIC. Recurring periods of thrombocytopenia and hemolysis, with neurologic or renal abnormalities, then occur. Alternatively, thrombocytopenia may be the only initial manifestation. Bleeding manifestations can be severe, including intracranial hemorrhage, primarily due to the thrombocytopenia. 92 Patients may be mistakenly diagnosed with Evans syndrome. Of note, despite the severe congenital hemolytic anemia, the diagnosis in many of the cases reported to date is made later in childhood or even adulthood. 83 Older children can present with typical clinical features of TTP. These include neurologic changes (seizures, altered mental status, focal neurologic deficits) 89 renal impairment, 93 schistocytic hemolytic anemia, and thrombocytopenia. Factors that can trigger TTP in older individuals with familial disease include pregnancy, infection, stress, or alcohol consumption. 86 Rarely, cardiac involvement has been reported. 94 Genetics Most children with familial TTP are born to asymptomatic parents, suggesting a usual autosomal recessive pattern. However, the finding of recurrent disease presenting in successive generations of adults suggests that for some patients there is an autosomal dominant inheritance. Consanguinity has been noted in some parents of children with congenital TTP.
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Laboratory Features
At presentation, children with chronic relapsing TTP usually present with a Coombs-negative hemolytic anemia. The anemia can be quite severe, with hemoglobin concentrations below 6 g/dL often described. 98 The platelet count is also reduced, often severely so. The coagulation profile (PT, aPTT, and fibrinogen) is usually normal, although coagulopathy has been reported in some cases. The lactate dehydrogenase (LDH) is elevated, the etiology of which is tissue ischemia rather than red blood cell breakdown. 99 Renal abnormalities including hematuria, proteinuria, and elevations in serum creatinine are not uncommon. The levels of vWF/ antigen (Ag) are increased in the plasma of patients with chronic relapsing TTP; however, because vWF is an acute phase reactant, this finding is not specific for the disorder. 100, 101 The ratio of vWF/antigen to vWF/Rco (Ristocetin cofactor) is often normal in patients with chronic relapsing TTP and is not a reliable marker for the presence of ULvWF multimers in the plasma. 100, 102 Specialized laboratories can provide confirmatory studies. ULvWF multimers are present in familial TTP in remission, but decrease during relapses. 103 Increased levels of vWF propolypeptide (vWF/Ag II), a marker for endothelial cell injury, have been shown in TTP. 104 Furlan et al 100 demonstrated severely deficient levels of ADAMTS13 in four patients, including two siblings with chronic relapsing TTP in whom they could find no evidence of an inhibitor to the enzyme activity. Subsequently, several investigators have confirmed that there is severe deficiency of ADAMTS13 (< .05 U/dL) in patients with congenital TTP. 83, 95 Asymptomatic family relatives have mild decreases in ADAMTS13, with levels about averaging approximately 0.5 U/mL. 83, 95 The difficulty with the ADAMTS13 assay is demonstrated by the following case. Savasan et al 105 reported on a child who had recurrent schistocytic hemolytic anemia beginning in infancy with ULvWF and a requirement for recurrent plasma infusions to maintain clinical remission, but whose ADAMTS13 was normal. However, the infant was subsequently shown to have a mutation in the gene coding for ADAMTS13 and subnormal levels when measured by the sodium dodecyl sulfate polyacrylamide gel electrophoresis and immunoblotting technique. 97 The correlation between ADAMTS13 and ULvWF is not complete. Remuzzi et al 49 found patients who had absent ADAMTS13 activity but whose plasma did not contain ULvWF multimers, whereas other patients with TTP or atypical HUS had ULvWF multimers with intact ADAMTS13.
It also should be noted that newborns have large vWF multimers. [106] [107] [108] The ULvWF multimer appears to occur more commonly in the premature infant and disappears by 51 weeks gestational age. 106 There are conflicting reports regarding ADAMTS13 activity in the neonate. Some investigators have reported that vWF-cleaving protease activity is approximately 50% of adult levels in the neonate. [109] [110] [111] However, Tsai et al 107 found that ADAMTS13 activity was normal in nearly all newborns tested. Similarly, Schmugge et al 112 found that ADAMTS13 was normal in 74% of cord blood tested, but the remainder had activity of approximately 50% of adult normal that reached adult normal levels by 2 to 3 days. The discrepancy in results may be due to methodology, variation in the ADAMTS13 assay, or in specimen acquisition. In a small series, the levels in premature infants correlated with gestational age and birth weight; however, statistical difference between the preterm and term infants was not achieved, perhaps due to the small number of infants enrolled. 109 
Gene Analysis
More than 50 mutations of ADAMTS13 causing congenital TTP have been described. 113 Gene abnormalities include missense mutations leading to single amino acid substitutions, as well as nonsense, splicing, and frameshift mutations. In most cases, the gene product leads to greatly reduced secretion of ADAMTS13. 48 Many of these mutations have been reviewed recently. 114 Most patients with inherited TTP have compound heterozygous defects in their ADAMTS13 gene, although homozygous defects have been described. 114 Diagnostic Work-Up The diagnosis of TTP can usually be made with a combination of clinical symptoms, schistocytic hemolytic anemia, thrombocytopenia, and elevation in serum LDH. In their review of patients diagnosed in childhood with TTP, Schneppenheim et al 115 identified many children previously diagnosed with ITP or Evans syndrome. In Evans syndrome, the Coombs test is usually positive and there are prominent spherocytes on the peripheral blood smear. Typically, coagulopathy with hypofibrinogenemia is present in DIC. Because of the rapid progression of symptoms, plasma infusions or plasmapheresis should be initiated as soon as the diagnosis is entertained. Hence, the clinical response to therapy may confirm the diagnosis.
In general, ADAMTS13 activity and inhibitor determination are not readily available. However, given that most of their patients eventually did have the more serious manifestations of TTP with potentially life-threatening effects, Schneppenheim et al 115 have proposed that vWF-cleaving protease activity be determined in children with Coombs-negative Evans syndrome, relapsing parainfectious thrombocytopenia, thrombocytopenia with neurologic symptoms, atypical HUS, and even chronic thrombocytopenia.
Treatment
An ADAMTS13 threshold activity of above 0.05 U/mL appears to be adequate to prevent formation of microthrombi. 96 The half-life of vWF-cleaving protease appears to be quite long-in excess of 2 days. 96, 116 Therefore, infusion of 10 cm 3 /kg of FFP every 2 to 3 weeks has maintained clinical remission in patients with chronic relapsing TTP, 96, 98, 117 although prolonged remission with lower volumes of plasma has been reported. 96 Other products such as cryoprecipitate, cryoprecipitate supernatant, 118 solvent/detergent-treated plasma, 117, 119 and intermediate-purity factor VIII (FVIII) concentrates have been used to treat children with congenital deficiency of ADAMTS13. 95 It should be noted that there is significant variation in the ADAMTS13 activity in plasma-derived FVIII concentrates, and that clinical failure has been noted when concentrates, subsequently shown to have low amounts of enzyme, were used. 95 Recombinant and monoclonally purified FVIII concentrates do not contain significant quantities of ADAMTS13 and should not be used in therapy for congenital TTP. 95 Prognosis If the diagnosis is made and plasma infusions are continued, the long-term outlook appears to be related to damage that has occurred prior to initiation of therapy; for instance, kernicterus due to perinatal hyperbilirubinemia. Long-term neurologic sequelae from stroke or intracranial hemorrhage can also be present.
ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA
Etiology
As with adults, most cases of acquired TTP in children and adolescents are due to the development of an inhibitor to ADAMTS13. Such antibodies may develop idiopathically or in conjunction with other autoimmune disease. The association between acquired TTP and systemic lupus erythematosus (SLE) may be significantly greater in children and adolescents than in adults. Brunner et al 120 found that of 35 patients identified in their institution and in a literature review, 26% met the criteria for SLE and an additional 23% had incipient SLE. Chak et al 121 identified 21 pediatric patients with TTP and SLE. In four of these patients, the SLE preceded the diagnosis of TTP by up to 5 years, in nine of the patients the two disorders were diagnosed concurrently, and in the remaining eight patients the diagnosis of TTP preceded the diagnosis of SLE by 4 months to 5 years. Inhibitors to ADAMTS13 have been documented in a 12-year-old patient with SLE and TTP. 122 Although familial TTP is usually due to mutations in the ADAMTS13 gene, in one case, identical twins were shown to have acquired TTP caused by an inhibitor to ADAMTS13. 123 Acquired TTP also occurs in the posttransplantation setting, especially following bone marrow TTP AND HUS IN CHILDREN AND ADOLESCENTS/LOWE, WERNER transplantation (BMT). Most series of posttransplantation TTP have not separated pediatric from adult patients. The incidence of TTP occurring in patients undergoing allogeneic BMT has been reported at 0.5 to 8% or greater. [124] [125] [126] Ruutu et al 126 found the rate of TTP to be 5.4% of 87 patients < 20 years of age compared with 6.2% of 184 patients who were 20 to 40 years old and 8.1% of 135 patients > 40 years old (p ¼ not significant). In a series of 22 patients with post-BMT TTP, six were < 17 years of age. In this small series, TTP was associated with increased age, female gender, and possibly the use of unrelated donors. 125 Uderzo et al 86 described a very high incidence of 21% in children undergoing BMT for leukemia. In this series, an increased rate was noted in patients undergoing unrelated BMT. TTP after BMT does not appear to be due to deficiency of ADAMTS13. 124, 127, 128 Increased levels of vWF Ag have been noted.
Clinical Presentation
The clinical presentation of acquired TTP in childhood is identical to that of adults. As for chronic relapsing TTP, the presenting features include varying degrees of neurologic abnormalities, renal abnormalities, and fever. Petechiae, ecchymoses, gingival bleeding, hematuria, and bleeding from thrombocytopenia are common. Although acquired TTP usually occurs in older children and adolescents, it can occur in infancy. [129] [130] [131] Horton et al 130 identified acquired TTP as the cause of thrombocytopenia in 1.3% of nonneonates referred for evaluation of thrombocytopenia. In the series by Horton et al, five of seven had neurologic manifestations within 24 hours of presentation, of which two were intracranial hemorrhage.
Laboratory Features
The basic laboratory features of acquired TTP in childhood are essentially the same as those described for chronic relapsing TTP. The diagnosis can be made when the appropriate clinical features are matched with microangiopathic hemolytic anemia, an elevated LDH, and normal coagulation studies, and other causes (such as drug-induced, post-bone marrow transplantation, and pregnancy-induced [hemolysis, elevated liver enzymes, and low platelet count syndrome] illnesses) have been excluded. As with adults, many children with acquired TTP have antibodies against ADAMTS13. Hence they have severe deficiency of that enzyme with a documented inhibitor. As previously stated, most patients with typical HUS have normal values for ADAMTS13, hence this may help distinguish TTP from HUS in difficult cases. 132 ULvWF multimers were not apparent and ADAMTS13 plasma levels were normal in six patients with TTP acquired after BMT. 127 Diagnostic Work-Up The diagnostic evaluation of the patient with apparent acquired TTP begins with the history, including current medications and recent concomitant medical illness. Of course, the history of prior organ transplantation, especially BMT, is especially relevant. With the exception of cyclosporine, medications thus far implicated as causes of TTP (including ticlopidine, quinine, and clopidogrel) are rarely used in the pediatric population. The presence of prosthetic cardiac devices can induce severe microangiopathic hemolytic anemia with hemoglobinuria and decreased vWF multimers, known as the WaringBlender syndrome.
The laboratory assessment to rule out other microangiopathic disorders such as DIC is essentially the same as for congenital relapsing TTP, including coagulation studies such as a PT, aPTT, and fibrinogen; a Coombs test, and evaluation of the peripheral blood smear. The LDH is usually very elevated and renal dysfunction is variably present. Serologic studies to evaluate the presence of SLE, other autoimmune disorders, or possible infection should be performed, especially if consideration is given to include intravenous gamma globulin in the management.
In most patients with acquired autoimmune TTP, the ADAMTS13 level is very low (< 0.05 U/mL). The presence of inhibitors to ADAMTS13 is used to differentiate congenital relapsing TTP from acquired TTP. As noted, the levels of ADAMTS13 are normal or only slightly reduced in patients with diarrheal-associated HUS, post-BMT TTP, and many forms of druginduced TTP.
Treatment
Plasma exchange transfusion (PET) is the only treatment to date with efficacy proven by randomized clinical trial. In 1991, two studies both documented its efficacy. Compared with fresh frozen plasma infusions in patients, all of whom also received antiplatelet therapy, Rock et al 133 showed a decrease in mortality at 9 days (4 versus 16%) and 6 months (22 versus 37%). There was also a significantly increased response rate for improved platelet counts in the PET group. Other studies have confirmed improved survival with PET compared with plasma infusions. [134] [135] [136] PET should be initiated as soon as the diagnosis is considered seriously. Usually daily, single-volume PET is used, although more frequent exchanges may be considered for patients with refractory disease. 137 PET can be continued until clinical remission occurs, and then gradually tapered with monitoring of the patient for clinical and/or laboratory recurrence. There are significant complications to TTP, including catheter-related problems (infection, thrombosis, insertion complications), allergic reactions to plasma, and persistent thrombocytopenia. 135, 138 FFP infusions were shown to be less effective that PET, but could be used in the short term if PET is not available. Coppo et al 139 showed similar survival and relapse rates in a small, nonrandomized retrospective study comparing high-volume FFP (mean 27.5 mL/kg/ day) with PET as initial therapy; however, 42% of the patients in the FFP group were switched to PET.
The use of additional modalities in the management of patients with TTP is less clear. In many case series, corticosteroids and/or antiplatelet agents have been used with PET in the initial management of patients with TTP, but their role generally has not been studied by randomized clinical trial. Bobbio-Pallavicini et al 140 found no significant difference in response rate, survival, or bleeding symptoms in a study of antiplatelet therapy when added to corticosteroids and PET. Nevertheless, there are concerns about the risk for increased bleeding with the use of antiplatelet agents. PET has not been proven to be efficacious for patients with posttransplantation TTP.
For patients who fail to respond adequately to plasmapheresis or who cannot be weaned off of plasmapheresis, several other modalities have been usedagain, without the benefit of randomized controlled clinical trials to prove efficacy. Vincristine has been used in both adolescent and adult patients. 141, 142 Similarly, there are several case reports including adolescents using cyclosporine to treat TTP, 141, 143 although caution should be used because this drug can be a cause of the disorder. Other agents include intravenous gamma globulin 144 (although benefit was not seen in a small retrospective review 145 ) and rituximab. 146, 147 Splenectomy has been used to treat patients with multiply relapsing TTP or unresponsive TTP with apparent efficacy. 66, 148, 149 Laparoscopic splenectomy has been performed safely. 150 None of these studies has addressed the impact of splenectomy for TTP in the pediatric age group.
For patients with drug-induced TTP, removal of the offending agent is an important first step. Ticlopidine-and clopidogrel-induced TTP may have an autoimmune basis.
Supportive care is important in the management of patients with TTP. Red blood cell transfusion frequently is required. Platelet transfusion should be used only for life-threatening hemorrhage. 
